- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07685522
Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.
The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Shawn M Patterson
- Telefoonnummer: 7164323545
- E-mail: spatterson@egrethealthcareventure.com
Studie Contact Back-up
- Naam: Erin M Garcia
- Telefoonnummer: 716-863-2552
- E-mail: egarcia@egrethealthcareventures.com
Studie Locaties
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polen, 61-848
- Nog niet aan het werven
- Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
-
Hoofdonderzoeker:
- Aleksander Araszkiewicz, Professor, MD, PhD
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-202
- Werving
- Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
-
Hoofdonderzoeker:
- Grzegorz Kopeć, Professor, MD, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
Subjects must meet all following general inclusion criteria:
- Age ≥ 18 and ≤ 75 years.
- Clinical signs, symptoms, and presentation consistent with acute PE;
- PE symptom duration ≤ 14 days;
- CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
- RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
- Systolic blood pressure ≥ 90 mmHg;
- Stable heart rate < 130 BPM prior to procedure;
- Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
- Informed Consent Form signed
- Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit
Exclusion Criteria:
Subjects must not meet any of the following general exclusion criteria:
- Thrombolytic use within 30 days of baseline CT angiogram
- Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
- Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
- FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
- Hematocrit < 28%;
- Platelets < 100,000/ML;
- Serum creatinine > 1.8 mg/dL;
- International normalized ratio (INR) > 3;
- Major trauma injury severity score (ISS) > 15 within the past 14 days
- Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
- Cardiovascular or pulmonary surgery within last 7 days;
- Actively progressing cancer requiring chemotherapy
- Known bleeding diathesis or coagulation disorder;
- Left bundle branch block;
- History of severe or chronic pulmonary arterial hypertension;
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
- History of uncompensated heart failure;
- History of underlying lung disease that is oxygen dependent;
- History of chest irradiation;
- History of heparin-induced thrombocytopenia (HIT);
- Patients who are under intubation
- Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
- Life expectancy of < 90 days, as determined by Investigator;
- Female who is pregnant or nursing;
- Current participation in another investigational drug or device treatment study
- History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
- Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Toestel Haalbaarheid
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
|
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety Endpoint: Major Adverse Events
Tijdsspanne: 48 hours
|
Major Adverse Events, a composite of:
|
48 hours
|
|
Efficacy Endpoint: Reduction in RV/LV Ratio
Tijdsspanne: 48 hours
|
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
|
48 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety Endpoint: Device-Related Death
Tijdsspanne: 48 hours
|
Device-related death within 48 hours
|
48 hours
|
|
Safety Endpoint: Major Bleeding
Tijdsspanne: 48 Hours
|
Major bleeding within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Clinical Deterioration
Tijdsspanne: 48 Hours
|
Device-related clinical deterioration within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Pulmonary Vascular Injury
Tijdsspanne: 48 Hours
|
Device-related pulmonary vascular injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Cardiac Injury
Tijdsspanne: 48 Hours
|
Cardiac injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Any-Cause Mortality
Tijdsspanne: 30 Days
|
Any-cause mortality within 30 days
|
30 Days
|
|
Safety Endpoint: Device-Related Serious Adverse Event
Tijdsspanne: 30 Days
|
Device-related Serious Adverse Events (SAEs) within 30 days
|
30 Days
|
|
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
Tijdsspanne: 30 Days
|
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
|
30 Days
|
|
Efficacy Endpoint: Modified Miller Index Score
Tijdsspanne: 48 Hours
|
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
|
48 Hours
|
|
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
Tijdsspanne: Procedure
|
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Change in Cardiac Index
Tijdsspanne: Procedure
|
Procedural change in cardiac index [measured in L/min/m^2]
|
Procedure
|
|
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
Tijdsspanne: 30 Days
|
Length of stay in the ICU associated with the index procedure [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Length of Total Hospital Stay
Tijdsspanne: 30 Days
|
Length of total hospital stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
Tijdsspanne: 30 Days
|
Post-index-procedure hospital length of stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
Tijdsspanne: Procedure
|
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
Tijdsspanne: Procedure
|
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
Tijdsspanne: Procedure
|
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
|
Procedure
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Tijdsspanne: 48 Hours
|
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
|
48 Hours
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Tijdsspanne: 30 Days
|
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
|
30 Days
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 26-VIC-0001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .